Joseph C Francisco from Silverdale, WA, age 30

Joseph Francisco

Joseph J. Francisco

view source

Specialties:

Podiatric Medicine

Work:

Southwood Physician Services
7641 Market St STE 5, Youngstown, OH 44512
(330)9654830 (phone), (330)9654831 (fax)

Languages:

English

Description:

Dr. Francisco works in Youngstown, OH and specializes in Podiatric Medicine. Dr. Francisco is affiliated with Salem Regional Medical Center, St Elizabeth Health Center and Valleycare Northside Medical Center.

Joseph Francisco

view source

Joseph Justin Francisco

view source

Joseph Francisco

view source

Joseph Francisco

view source

Joseph Francisco

view source

Joseph Anthony Francisco

License #:

C009453 - Active

Category:

Social Work

Issued Date:

Apr 10, 2015

Expiration Date:

Jun 30, 2017

Type:

Clinical Social Worker

Us Patents

Nucleic Acids Encoding Anti-Cd40 Proteins And Methods Of Producing Recombinant Anti-Cd40 Proteins
view source
US Patent:

6838261, Jan 4, 2005
Filed:

Nov 28, 2000
Appl. No.:

09/724409
Inventors:

Clay B. Siegall - Edmonds WA, US
Alan F. Wahl - Mercer Island WA, US
Joseph A. Francisco - Edmonds WA, US
Assignee:

Seattle Genetics, Inc. - Bothell WA
International Classification:

C07H 2104
C12N 119
C12N 121
C12N 516
C12N 1500
US Classification:

435 696, 435328, 435334, 4353431, 536 2353
Abstract:

The present invention relates to methods and compositions for the prevention and treatment of cancer, inflammatory diseases and disorders or deficiencies of the immune system. The methods of the invention comprise administering a CD40 binding protein that potentiates the binding of CD40 to CD40 ligand.

Methods For The Treatment And Prevention Of Cancer Using Anti-Cd40 Antibodies
view source
US Patent:

6843989, Jan 18, 2005
Filed:

Nov 28, 2000
Appl. No.:

09/724530
Inventors:

Clay B. Siegall - Edmonds WA, US
Alan F. Wahl - Mercer Island WA, US
Joseph A. Francisco - Edmonds WA, US
Assignee:

Seattle Genetics, Inc. - Bothell WA
International Classification:

A61K 39395
C07K 1618
C07K 1628
US Classification:

4241301, 4241331, 4241341, 4241351, 4241411, 4241441, 4241531, 4241551, 4241731, 4241741, 4241781, 4241811, 4241831, 5303871, 5303873, 5303881, 53038822, 53038873, 5303888, 53038885, 5303911, 5303917
Abstract:

The present invention relates to methods and compositions for the prevention and treatment of cancer, inflammatory diseases and disorders or deficiencies of the immune system. The methods of the invention comprise administering a CD40 binding protein that potentiates the binding of CD40 to CD40 ligand.

Recombinant Anti-Cd40 Antibody And Uses Thereof
view source
US Patent:

6946129, Sep 20, 2005
Filed:

Jun 8, 1999
Appl. No.:

09/328296
Inventors:

Clay B. Siegall - Edmonds WA, US
Alan F. Wahl - Mercer Island WA, US
Joseph A. Francisco - Edmonds WA, US
Assignee:

Seattle Genetics, Inc. - Bothell WA
International Classification:

A61K039/395
C07K016/18
C07K016/28
US Classification:

4241301, 4241331, 4241341, 4241351, 4241411, 4241441, 4241531, 4241551, 4241731, 4241741, 4241781, 4241811, 4241831, 5303871, 5303873, 5303881, 53038822, 53038873, 5303883, 53038885, 5303911, 5303917
Abstract:

The present invention relates to methods and compositions for the prevention and treatment of cancer, inflammatory diseases and disorders or deficiencies of the immune system. The methods of the invention comprise administering a CD40 binding protein that potentiates the binding of CD40 to CD40 ligand.

Recombinant Anti-Cd30 Antibodies And Uses Thereof
view source
US Patent:

7090843, Aug 15, 2006
Filed:

Nov 28, 2000
Appl. No.:

09/724406
Inventors:

Joseph A. Francisco - Edmonds WA, US
Grant Risdon - Clayton MO, US
Alan F. Wahl - Mercer Island WA, US
Clay Siegall - Edmonds WA, US
Assignee:

Seattle Genetics, Inc. - Bothell WA
International Classification:

A61K 39/395
US Classification:

4241381, 4241411, 4241551, 4241341, 4241331
Abstract:

The present invention relates to methods and compositions for the treatment of Hodgkin's Disease, comprising administering proteins characterized by their ability to bind to CD30, or compete with monoclonal antibodies AC10 or HeFi-1 for binding to CD30, and exert a cytostatic or cytotoxic effect on Hodgkin's Disease cells. Such proteins include derivatives of monoclonal antibodies AC10 and HeFi-1. The proteins of the invention can be human, humanized, or chimeric antibodies; further, they can be conjugated to cytotoxic agents such as chemotherapeutic drugs. The invention further relates to nucleic acids encoding the proteins of the invention. The invention yet further relates to a method for identifying an anti-CD30 antibody useful for the treatment or prevention of Hodgkin's Disease.

Methods For Treating Immune Disorders Or Cancer With Anti-Cd40 Antibodies
view source
US Patent:

7498032, Mar 3, 2009
Filed:

May 14, 2004
Appl. No.:

10/846981
Inventors:

Clay B. Siegall - Edmonds WA, US
Alan F. Wahl - Mercer Island WA, US
Joseph A. Francisco - Edmonds WA, US
Assignee:

Seattle Genetics, Inc. - Bothwell WA
International Classification:

A61K 39/395
C07K 16/28
US Classification:

4241531, 4241301, 4241331, 4241411, 4241431, 4241441, 4241521, 4241731, 5303871, 5303873, 5303881, 5303882, 53038822, 5303887, 53038873
Abstract:

The present invention relates to methods and compositions for the prevention and treatment of cancer, inflammatory diseases and disorders or deficiencies of the immune system. The methods of the invention comprise administering a CD40 binding protein that potentiates the binding of CD40 to CD40 ligand.

Methods For The Treatment Of Cancer Using Anti-Cd40 Antibodies
view source
US Patent:

7510711, Mar 31, 2009
Filed:

Apr 8, 2005
Appl. No.:

11/102743
Inventors:

Clay B. Siegall - Edmonds WA, US
Alan F. Wahl - Mercer Island WA, US
Joseph A. Francisco - Edmonds WA, US
Assignee:

Seattle Genetics, Inc. - Bothell WA
International Classification:

A61K 39/395
C07K 16/28
US Classification:

4241531, 4241301, 4241331, 4241411, 4241431, 4241441, 4241731, 5303871, 5303873, 5303882, 53038822, 5303887, 53038873
Abstract:

The present invention relates to methods and compositions for the prevention and treatment of cancer, inflammatory diseases and disorders or deficiencies of the immune system. The methods of the invention comprise administering a CD40 binding protein that potentiates the binding of CD40 to CD40 ligand.

Methods For Augmenting An Immune Response Using Anti-Cd40 Antibodies
view source
US Patent:

7824683, Nov 2, 2010
Filed:

Dec 28, 2009
Appl. No.:

12/648108
Inventors:

Clay B. Siegall - Edmonds WA, US
Alan F. Wahl - Mercer Island WA, US
Joseph A. Francisco - Edmonds WA, US
Assignee:

Seattle Genetics, Inc. - Bothell WA
International Classification:

A61K 39/395
C07K 16/28
US Classification:

4241531, 4241301, 4241331, 4241411, 4241431, 4241441, 4241521, 4241731, 5303871, 5303873, 5303881, 5303882, 53038822, 5303887, 53038873
Abstract:

The present invention relates to methods and compositions for the prevention and treatment of cancer, inflammatory diseases and disorders or deficiencies of the immune system. The methods of the invention comprise administering a CD40 binding protein that potentiates the binding of CD40 to CD40 ligand.

Recombinant Anti-Cd30 Antibodies And Uses Thereof
view source
US Patent:

20040018194, Jan 29, 2004
Filed:

May 28, 2003
Appl. No.:

10/447257
Inventors:

Joseph Francisco - Edmonds WA, US
Grant Risdon - Seattle WA, US
Alan Wahl - Mercer Island WA, US
Clay Siegall - Edmonds WA, US
Peter Senter - Seattle WA, US
Sveltana Doronina - Snohomish WA, US
Brian Toki - Lynnwood WA, US
International Classification:

A61K039/395
C07K016/30
US Classification:

424/144100, 530/388220
Abstract:

The present invention relates to methods and compositions for the treatment of Hodgkin's Disease, comprising administering proteins characterized by their ability to bind to CD30, or compete with monoclonal antibodies AC10 or HeFi-1 for binding to CD30, and exert a cytostatic or cytotoxic effect on Hodgkin's disease cells in the absence of effector cells or complement. Such proteins include derivatives of monoclonal antibodies AC10 and HeFi-1. The proteins of the invention can be human, humanized, or chimeric antibodies; further, they can be conjugated to cytotoxic agents such as chemotherapeutic drugs. The invention further relates to nucleic acids encoding the proteins of the invention. The invention yet further relates to a method for identifying an anti-CD30 antibody useful for the treatment or prevention of Hodgkin's Disease.